Evidence map›Paper›PMID 28903071›Full record

ArticleMicrobes and infection2017

Highly conserved M2e and hemagglutinin epitope-based recombinant proteins induce protection against influenza virus infection.

Yan Guo, Lei He, Nianping Song, Pei Li, Shihui Sun, Guangyu Zhao, Wanbo Tai, Shibo Jiang, Lanying Du, Yusen Zhou

Abstract read
In one paragraph

Article in Microbes and infection, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. The Quest for a Truly Universal Influenza Vaccine.Frontiers in cellular and infection microbiology · 2019
    Review
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Yan GuoState Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China.
Lei HeGraduate School of Guangxi Medical University, Nanning, Guangxi, China.
Nianping SongState Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China.
Pei LiState Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China.
Shihui SunState Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China.
Guangyu ZhaoState Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China.
Wanbo TaiState Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China; Lindsley F. Kimball Research Institute, New York Blood Center, New York, USA.
Shibo JiangLindsley F. Kimball Research Institute, New York Blood Center, New York, USA.
Lanying DuLindsley F. Kimball Research Institute, New York Blood Center, New York, USA. Electronic address: ldu@nybc.org.
Yusen ZhouState Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China; Graduate School of Guangxi Medical University, Nanning, Guangxi, China. Electronic address: Yszhou@bmi.ac.cn.
Institute of Microbiology · CNNew York Blood Center · USGuangxi Medical University · CN

Funding

B. subtilis spore-delivered M2e-FP-based mucosal universal influenza vaccinesR21AI111152 · NIAID · NEW YORK BLOOD CENTER · PI DU, LANYING · 2014 to 2015
$470k
NIAID NIH HHS R21 AI111152
6 · The paper itself

Abstract

Highly pathogenic influenza viruses continue to cause serious threat to public health due to their pandemic potential, calling for an urgent need to develop effective, safe, convenient, and universal vaccines against influenza virus infection. In this study, we constructed two recombinant protein vaccines, 2H5M2e-2H7M2e-H5FP-H7FP (hereinafter M2e-FP-1) and 2H5M2e-H5FP-2H7M2e-H7FP (hereinafter M2e-FP-2), by respectively linking highly conserved sequences of two molecules of ectodomain of M2 (M2e) and one molecule of fusion peptide (FP) epitope of hemagglutinin (HA) of H5N1 and H7N9 influenza viruses in different orders. The Escherichia coli-expressed M2e-FP-1 and M2e-FP-2 proteins induced similarly high-titer M2e-FP-specific antibodies in the immunized mice. Importantly, both proteins were able to prevent lethal challenge of heterologous H1N1 influenza virus, with significantly reduced viral titers and alleviated pathological changes in the lungs, as well as increased body weight and complete survivals, in the challenge mice. Taken together, our study demonstrates that highly conserved M2e and FP epitope of HA of H5N1 and H7N9 influenza viruses can be used as important targets for development of safe and economical universal influenza vaccines, and that the position of H7N9 M2e and H5N1 HA epitope sequences in the vaccine components has no significant effects on the immunogenicity and efficacy of M2e-FP-based subunit vaccines.

Indexed as

AnimalsAntibodies, ViralFemaleHemagglutinin Glycoproteins, Influenza VirusInfluenza A Virus, H1N1 SubtypeInfluenza A Virus, H5N1 SubtypeInfluenza A Virus, H7N9 SubtypeInfluenza VaccinesMiceMice, Inbred BALB COrthomyxoviridae InfectionsVaccinationVaccines, SubunitVaccines, SyntheticViral ProteinsAntibodies, ViralHemagglutinin Glycoproteins, Influenza VirusInfluenza VaccinesVaccines, SubunitVaccines, SyntheticViral ProteinsHemagglutinin fusion peptideInfluenza virusM2eProtectionUniversal vaccines

Identifiers

PMID28903071
PMCPMC7110499
OpenAlexW2752492018

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.